6 terminated, 3 completed, 1 not yet recruiting, 1 unknown. 11 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Terminated 6, Completed 3, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Vaso-occlusive Crisis: new trials by email Literature Review of Vaso-occlusive Crisis trials Research Report on Vaso-occlusive Crisis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric Sufentanil - Vaso-occlusive Crisis | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 182 | 2024-05-02 | 2023-12-26 |
| Hyperbaric-oxygen Therapy (HBOT) Versus Placebo for Treating Vaso-Occlusive Crisis (VOC) in Sickle Cell Disease (SCD) HBOT in Hyperbaric chamber, Hyperbaric chamber for placebo - Sickle Cell Disease, Hyperbaric Oxygen Therapy | Phase 3 | Unknown | University Hospital, Geneva | 100 | 2022-09-15 | 2022-11-02 |
| A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Inclacumab - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Terminated | Pfizer | 242 | 2022-03-29 | 2025-12-17 |
| A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises Inclacumab, Placebo - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Terminated | Pfizer | 72 | 2021-12-09 | 2024-12-11 |
| A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises Inclacumab, Placebo - Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Completed | Pfizer | 241 | 2021-10-04 | 2025-12-02 |
| Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED Intranasal ketamine - Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease | Phase 3 | Terminated | Abigail Nixon | 5 | 2019-12-19 | 2024-11-18 |
| Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia Omega 3, Vit D, Zinc sulfate - Vaso-occlusive Crisis, Sickle Cell Disease | Phase 2 / Phase 3 | Completed | Beni-Suef University | 350 | 2019-11-01 | 2021-01-27 |
| Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease Rivipansel - Sickle Cell Anemia, Sickle Cell Disease | Phase 3 | Terminated | GlycoMimetics Incorporated | 154 | 2015-12-16 | 2021-02-10 |
| Apixaban in Patients With Sickle Cell Disease Apixaban, Placebo - Vaso-occlusive Crisis, Reduction in Hospitalizations | Phase 3 | Terminated | Nirmish Shah | 16 | 2015-01-01 | 2020-03-11 |
| Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) Saline, MST-188 - Vaso-occlusive Crisis, Sickle Cell Disease | Phase 3 | Completed | Mast Therapeutics, Inc. | 388 | 2013-05-01 | 2016-10-28 |
| Steroid Treatment for Sickle Cell Pain Crisis Steroid arm, Placebo - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 3 | Terminated | Baylor College of Medicine | 18 | 2005-12-01 | 2020-07-07 |
Vaso-Occlusive Crises (11) · Anemia, Sickle Cell (10) · Hematologic Diseases (3) · Sickle Cell Trait (2) · Agnosia (1)
Anemia (11) · Anemia, Hemolytic (11) · Anemia, Hemolytic, Congenital (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Genetic Diseases, Inborn (11) · Hemic and Lymphatic Diseases (11) · Hemoglobinopathies (11) · Hematologic Diseases (8) · Anemia, Sickle Cell (1) · Nervous System Diseases (1) · Neurobehavioral Manifestations (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Perceptual Disorders (1) · Signs and Symptoms (1)
inclacumab (3) · Cardiovascular Agents (1) · Docosahexaenoic Acids (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Hydroxyurea (1) · Hyperbaric Oxygenation (1) · Morphine (1) · Simvastatin (1) · Sodium Chloride (1) · Sufentanil (1) · Zinc Sulfate (1) · apixaban (1) · rivipansel (1)
Pfizer (3) · Abigail Nixon (1) · Assistance Publique - Hôpitaux de Paris (1) · Baylor College of Medicine (1) · Beni-Suef University (1) · GlycoMimetics Incorporated (1) · Mast Therapeutics, Inc. (1) · Nirmish Shah (1) · University Hospital, Geneva (1)
United States (8) · Brazil (4) · Lebanon (4) · Oman (4) · Saudi Arabia (4) · Turkey (Türkiye) (4) · Colombia (3) · France (3) · Kenya (3) · Nigeria (3) · Egypt (2) · Tanzania (2) · Belgium (1) · Canada (1) · Dominican Republic (1)
Ahmed F Mahmoud Hussein, MS.c (1) · Edwin L. Parsley, D.O. (1) · Nirmish Shah, MD (1)
2019 (2)